Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines.

Gottstein C, Wels W, Ober B, Thorpe PE.

Biotechniques. 2001 Jan;30(1):190-4, 196, 198 passim.

PMID:
11196310
2.

A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.

Cooke SP, Boxer GM, Lawrence L, Pedley RB, Spencer DI, Begent RH, Chester KA.

Cancer Res. 2001 May 1;61(9):3653-9.

4.
6.

VEGF-VEGF receptor complexes as markers of tumor vascular endothelium.

Brekken RA, Thorpe PE.

J Control Release. 2001 Jul 6;74(1-3):173-81. Review.

PMID:
11489493
7.

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.

Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T, Hicklin DJ, Bohlen P, Witte L.

Cancer Lett. 1999 Mar 1;136(2):203-13.

PMID:
10355750
8.

Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.

Clin Cancer Res. 2000 Mar;6(3):957-65.

9.
10.
11.

Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells.

Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y.

Oncogene. 2000 Apr 20;19(17):2138-46.

12.

Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.

Cao Y, Chen H, Zhou L, Chiang MK, Anand-Apte B, Weatherbee JA, Wang Y, Fang F, Flanagan JG, Tsang ML.

J Biol Chem. 1996 Feb 9;271(6):3154-62.

13.

Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis.

Oh H, Takagi H, Otani A, Koyama S, Kemmochi S, Uemura A, Honda Y.

Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):383-8. Epub 2001 Dec 26.

14.

A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability.

Stacker SA, Vitali A, Caesar C, Domagala T, Groenen LC, Nice E, Achen MG, Wilks AF.

J Biol Chem. 1999 Dec 3;274(49):34884-92.

15.
16.

Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803.

Tian X, Song S, Wu J, Meng L, Dong Z, Shou C.

Biochem Biophys Res Commun. 2001 Aug 24;286(3):505-12.

PMID:
11511087
17.

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.

Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62.

18.

Vascular endothelial growth factor as a marker of tumor endothelium.

Brekken RA, Huang X, King SW, Thorpe PE.

Cancer Res. 1998 May 1;58(9):1952-9.

19.

Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin.

Enholm B, Karpanen T, Jeltsch M, Kubo H, Stenback F, Prevo R, Jackson DG, Yla-Herttuala S, Alitalo K.

Circ Res. 2001 Mar 30;88(6):623-9. Erratum in: Circ Res 2001 Jul 6;89(1):E15.

20.

Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.

Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K, Oohashi H, Hara N.

Cancer Res. 2000 Apr 15;60(8):2169-77.

Supplemental Content

Support Center